It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Idiopathic inflammatory myopathies (IIMs) are severe autoimmune diseases with poorly understood pathogenesis and unmet medical needs. Here, we examine the role of interferon γ (IFNγ) using NOD female mice deficient in the inducible T cell co-stimulator (Icos), which have previously been shown to develop spontaneous IFNγ-driven myositis mimicking human disease. Using muscle proteomic and spatial transcriptomic analyses we reveal profound myofiber metabolic dysregulation in these mice. In addition, we report muscle mitochondrial abnormalities and oxidative stress in diseased mice. Supporting a pathogenic role for oxidative stress, treatment with a reactive oxygen species (ROS) buffer compound alleviated myositis, preserved muscle mitochondrial ultrastructure and respiration, and reduced inflammation. Mitochondrial anomalies and oxidative stress were diminished following anti-IFNγ treatment. Further transcriptomic analysis in IIMs patients and human myoblast in vitro studies supported the link between IFNγ and mitochondrial dysfunction observed in mice. These results suggest that mitochondrial dysfunction, ROS and inflammation are interconnected in a self-maintenance loop, opening perspectives for mitochondria therapy and/or ROS targeting drugs in myositis.
Idiopathic inflammatory myopathies are severe autoimmune diseases with poorly understood pathogenesis. In this study, the authors use Icos-deficient NOD mice as a model for myositis, as well as clinical samples, to demonstrate mitochondrial abnormalities and metabolic dysfunction, which can be reversed by treatment with the ROS scavenger, N-acetylcysteine (NAC).
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 FOCIS Center of Excellence PAn’THER, Univ Rouen Normandie, Inserm, UMR1234, Rouen, France (GRID:grid.7429.8) (ISNI:0000000121866389)
2 National Institutes of Health, Muscle Disease Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165); Johns Hopkins University School of Medicine, Department of Neurology, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311)
3 Inserm US 51, CNRS UAR 2026, HeRacLeS PISSARO, Univ Rouen Normandie, Rouen, France (GRID:grid.10400.35) (ISNI:0000 0001 2108 3034)
4 Inserm US 51, CNRS UAR 2026, HeRacLeS PISSARO, Univ Rouen Normandie, Rouen, France (GRID:grid.10400.35) (ISNI:0000 0001 2108 3034); INSA Rouen Normandie, CNRS, Normandie Univ, PBS UMR 6270, Univ Rouen Normandie, Rouen, France (GRID:grid.435013.0)
5 University of Strasbourg, Translational Medicine Federation of Strasbourg, Team 3072, Faculty of Medicine, Strasbourg, France (GRID:grid.11843.3f) (ISNI:0000 0001 2157 9291); Hôpitaux Universitaires de Strasbourg, Unité exploration fonctionnelle musculaire-service de physiologie, Centre National de Référence des Maladies Auto-Immunes Systémiques Rares de l’Est et du Sud-Ouest -Service de rhumatologie, Strasbourg, France (GRID:grid.412220.7) (ISNI:0000 0001 2177 138X)
6 University of Strasbourg, Translational Medicine Federation of Strasbourg, Team 3072, Faculty of Medicine, Strasbourg, France (GRID:grid.11843.3f) (ISNI:0000 0001 2157 9291)
7 Inserm US51, CNRS UAR2026, HeRacLeS PRIMACEN, Univ Rouen Normandie, Rouen, France (GRID:grid.10400.35) (ISNI:0000 0001 2108 3034)
8 Department of Pathology, CHU Rouen, Rouen, France (GRID:grid.41724.34) (ISNI:0000 0001 2296 5231)
9 BOSS facility, Univ Rouen Normandie, Inserm, UMR1096, Rouen, France (GRID:grid.7429.8) (ISNI:0000000121866389)
10 Paris Descartes University, Sorbonne Paris Cité, Cochin Institute, Paris, France (GRID:grid.508487.6) (ISNI:0000 0004 7885 7602)
11 National Institutes of Health, Muscle Disease Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165); Johns Hopkins University School of Medicine, Department of Neurology, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Johns Hopkins University School of Medicine, Department of Medicine, Division of Rheumatology, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311)
12 FOCIS Center of Excellence PAn’THER, Univ Rouen Normandie, Inserm, UMR1234, Rouen, France (GRID:grid.7429.8) (ISNI:0000000121866389); Department of Immunology and Biotherapy, CHU Rouen, Rouen, France (GRID:grid.41724.34) (ISNI:0000 0001 2296 5231)